Search Within

Andrew L. Laccetti

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (1)
Groups
  1. Department of Medicine (6)
  2. Epidemiology and Biostatistics (6)
  3. Genitourinary Oncology Service (6)
  4. Solid Tumor Oncology Division (6)
  5. Hematologic Malignancies, Division of (5)
  6. Weinberg Fellows (5)

More Groups

People
  1. David Aggen (5)
  2. Deaglan McHugh (5)
  3. Neil Shah (5)
  4. Ritesh Kotecha (5)
  5. Colette Owens (4)
  6. Andrea Knezevic (3)

More People

Years
  1. 2024 (3)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (1)
Publications
  1. Journal of Clinical Oncology (5)
  2. Annals of Oncology (1)
Publishers
  1. American Society of Clinical Oncology (5)
  2. Oxford University Press (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)
    Meeting Abstract

    Choudhury, A. D.; Heller, G.; Reimers, M. A.; Laccetti, A. L.; Smieliauskas, F.; Ravi, P.; Dooley, K.; Mazza, G. L.; Gartrell, B. A.; Steen, P. D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Bajorin, D. F.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Fitzgerald, K. N.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y. B.; Zucker, M.; Lefkowitz, R. A.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates
    Journal Article

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Zucker, M.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Dadoun, C.; Reznik, E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Reznik, E.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Tassone, D.; Dadoun, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save